Insulin Aspart Sanofi

Insulin Aspart, the active ingredient in Insulin Aspart Sanofi, is a rapid‑acting insulin analog presented as an injectable solution for subcutaneous use. It treats hyperglycemia in both type 1 and type 2 diabetes mellitus, providing a rapid onset of action within minutes to facilitate post‑meal glucose control.

GNH USA supplies Insulin Aspart Sanofi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company follows stringent quality standards and offers reliable cold‑chain logistics to ensure product integrity during global distribution.

Insulin Aspart is a rapid‑acting insulin analog used to manage blood glucose levels in diabetes mellitus.

- Type 1 diabetes mellitus: provides mealtime insulin to lower post‑meal blood glucose levels. - Type 2 diabetes mellitus: used as bolus insulin to control post‑prandial glucose excursions.

Adverse reactions may occur with any insulin therapy.

Common Side Effects: - Hypoglycemia: low blood glucose, especially if meals are missed or delayed. - Injection site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase due to improved glucose utilization.

Serious or Rare Side Effects: - Severe hypoglycemia: can lead to seizures, loss of consciousness, or coma. - Allergic reaction: rash, urticaria, or anaphylaxis requiring immediate medical attention. - Lipodystrophy: abnormal fat distribution at injection sites.

Patients should follow specific safety measures when using Insulin Aspart.

- Monitor blood glucose: adjust dose based on frequent glucose measurements. - Avoid missed meals: ensure carbohydrate intake after injection to prevent hypoglycemia. - Use with caution in renal impairment: reduced insulin clearance may increase hypoglycemia risk. - Pregnancy and lactation: discuss risks with a healthcare provider before use. - Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Insulin Aspart may interact with several medications, requiring attention to avoid or monitor effects.

Major Interactions (Avoid): - Concurrent use with sulfonylureas: increased risk of severe hypoglycemia. - Alcohol consumption: may potentiate insulin’s glucose‑lowering effect leading to hypoglycemia. - Beta‑blockers: can mask symptoms of hypoglycemia, making detection difficult.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may reduce insulin sensitivity, requiring dose adjustment. - Systemic corticosteroids: can raise blood glucose, potentially diminishing insulin effectiveness.